Afrezza
Payments companies reported to CMS as associated with Afrezza. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Afrezza, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Afrezza
These are the largest totals companies reported as associated with Afrezza. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Michael Friedman | Pasadena, CA | $58,836.20 | |
| Brandy Biederman | Hixson, TN | Family | $58,395.91 |
| Perry Herson | Williston Park, NY | $40,255.04 | |
| Veena Watwe | Houston, TX | Endocrinology, Diabetes & Metabolism | $27,914.24 |
| Kalpana Reddy | Flushing, NY | Endocrinology, Diabetes & Metabolism | $25,460.52 |
| Martin Sarkar | Frederick, MD | Endocrinology, Diabetes & Metabolism | $24,227.51 |
| Theofanis Mitsinikos | Stony Brook, NY | Endocrinology, Diabetes & Metabolism | $22,389.91 |
| Anastasios Manessis | New York, NY | Endocrinology, Diabetes & Metabolism | $19,689.95 |
| Michael Haller | Gainesville, FL | Pediatric Endocrinology | $16,494.88 |
| Misha Denham | Coral Gables, FL | Endocrinology, Diabetes & Metabolism | $15,841.70 |
Prescribed Afrezza?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.